Anti-NY-ESO-1 Antibody, clone 1J11 ZooMAb® Rabbit Monoclonal
SIGMA/ZRB1540 - recombinant, expressed in HEK 293 cells
Synonym: Cancer/testis antigen 1;Autoimmunogenic cancer/testis antigen NY-
Product Type: Chemical
antibody form | purified antibody |
antibody product type | primary antibodies |
biological source | rabbit |
clone | 1J11, recombinant monoclonal |
conjugate | unconjugated |
description | recombinant, expressed in HEK 293 cells |
enhanced validation | recombinant expression Learn more about Antibody Enhanced Validation |
epitope sequence | C-terminal half |
form | lyophilized |
greener alternative category | Aligned |
greener alternative product characteristics | Waste Prevention Designing Safer Chemicals Design for Energy Efficiency Learn more about the Principles of Green Chemistry . |
isotype | IgG |
mol wt | calculated mol wt 17.99 kDa |
observed mol wt ~18 kDa | |
packaging | antibody small pack of 25 μL |
product line | ZooMAb® learn more |
Protein ID accession no. | NP_001318 |
purified by | using Protein A |
Quality Level | 200 |
recombinant | expressed in HEK 293 cells |
shipped in | ambient |
species reactivity | human |
storage temp. | 2-8°C |
technique(s) | affinity binding assay: suitable |
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable | |
western blot: suitable | |
UniProt accession no. | P78358 |
Application: | Quality Control Testing Evaluated by Western Blotting in H1299 cell lysate. Western Blotting Analysis: A 1:1,000 dilution of this antibody detected NY-ESO-1 in H1299 cell lysate. Tested applications Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected NY-ESO-1 in U266B1 cell lysate. Affinity Binding Assay: A representative lot of this antibody bound NY-ESO-1 with a KD of 2.3 x 10-8 in an affinity binding assay. Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected NY-ESO-1 in human testis tissue sections. Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user |
Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
General description: | We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information. |
General description: | ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them. |
Immunogen: | KLH-conjugated linear peptide corresponding to 17 amino acids from the C-terminal half of human NY-ESO-1. |
Legal Information: | ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany |
Physical form: | Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL. |
Reconstitution: | 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type. |
Specificity: | Clone 1J11 is a Rabbit recombinant monoclonal antibody that specifically detects NY-ESO-1. It targets an epitope within 17 amino acids from the C-terminal half. |
Storage and Stability: | Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws. |
Target description: | Cancer/testis antigen 1 (UniProt: P78358; also known as Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, CT6.1, L antigen family member 2, LAGE-2) is encoded by the CTAG1A (also known as CTAG, CTAG1, ESO1, LAGE2, LAGE2A) gene (Gene ID: 1485) in human. NY-ESO-1 is a human tumor antigen of the cancer/testis family that is highly expressed in many poor-prognosis melanomas and in other cancer types. However, it is not detected in non-malignant tissues with the exception of germ cells and trophoblasts. It features a glycine-rich N-terminal region and contains a C-terminal hydrophobic tail with a Pcc-1 domain that potentially serves as membrane-associated domain. NY-ESO-1 is expressed from 18 weeks until birth in human fetal testis and in adult testis it is strongly expressed in spermatogonia and in primary spermatocytes, but not in post-meiotic cells or in testicular somatic cells. Although the exact function of NY-ESO-1 is still not clear, it has been speculated it might contribute to certain properties, such as immortality, self-renewal, migratory ability, and capacity to invade that favor tumor cell survival. NY-ESO-1 expression has been reported in a wide range of tumor types. On the basis of its immunogenicity, NY-ESO-1 is considered as one of the most attractive antigens for cancer immunotherapy. T cells engineered to express an affinity-enhanced T cell receptor (TCR) recognizing a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1 have been considered as an attractive method for treatment of myeloma and enhance long-term survival of cells. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Raza, A., et al. (2020). J. Transl. Med. 18(1); Article 140; Thomas, R., et al. (2018). Front. Immunol. 9; 947). |
WGK Germany | WGK 1 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Storage Temp. | 2-8°C |